Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655772 | 1.00 | LMNA (0.53) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL1946731 | 0.83 | L3MBTL1 (0.41) | L3MBTL1KEAP1 | |
| SCHEMBL7752769 | 0.82 | LMNA (0.67) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL5286958 | 0.80 | RAB9A (0.44) | LMNASMN1; SMN2KEAP1POLB | |
| SCHEMBL18667866 | 0.78 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL18667208 | 0.78 | LMNA (0.60) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL334927 | 0.77 | SLC1A3 (0.64) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL735799 | 0.77 | SLC1A3 (0.64) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL334926 | 0.77 | SLC1A3 (0.64) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL966270 | 0.77 | LMNA (0.63) | LMNASMN1; SMN2SLC1A3SLC1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247771-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-01 | — | — | US | disclosed |
| WO-2007098923-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247771-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS | HTR4, OPRM1, SLC6A4 | LMNA 4592/4885SMN1; SMN2 2245/4885SLC1A3 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.